A regulatory crosstalk in Down syndrome: competing mRNA-miRNA network by Scarpato, Margherita
 University of Naples 
“Federico II” 
 
 
PhD Program 
“Advanced Biology” 
(XXVII CICLO) 
 
Coordinator 
Prof. Luciano Gaudio 
 
A regulatory crosstalk in Down syndrome: 
competing mRNA-miRNA network 
 
 
 
Tutor:        PhD student: 
Prof. Giuseppe Saccone    Dr. Margherita Scarpato 
Co-Tutor: 
Prof. Alfredo Ciccodicola 
 
Academic Year 2013/2014
   
  i 
Table of Contents 
1	   Abstract	  (Italiano)	   1	  
2	   Abstract	  (English)	   3	  
3	   Introduction	   5	  
3.1	   Down	  syndrome	   5	  3.1.1	   Down	  syndrome	  as	  a	  multisystem	  disorder	   6	  3.1.2	   Embryogenesis	  and	  Down	  syndrome	   7	  3.1.3	   Chromosome	  21	  and	  gene	  expression	   7	  
3.2	   Beyond	  the	  gene	  dosage	  hypothesis	   10	  3.2.1	   ceRNA	  hypothesis	   12	  
3.3	   microRNAs	   13	  3.3.1	   miRNA	  biogenesis	   14	  3.3.2	   miRNA-­‐mediated	  silencing	   16	  
4	   Aim	   19	  
5	   Methods	   21	  
5.1	   Data	  processing	  and	  bioinformatics	  analysis	   21	  5.1.1	   Expression	  data	  sets	  description	  and	  processing	   21	  5.1.2	   mRNA-­‐miRNA	  interactions	  prediction	   22	  5.1.3	   Data	  integration	  and	  biclustering	  analysis	   22	  5.1.4	   Differential	  gene	  expression	  in	  DS	  embryos	   23	  
5.2	   Generation	  of	  plasmid	  constructs	   23	  
5.3	   Cell	  culture	  and	  transfection	   25	  
5.4	   RNA	  extraction	  and	  Reverse	  Transcription	   25	  
5.5	   Quantitative	  Real-­‐Time	  PCR	   26	  
6	   Results	   29	  
6.1	   Gene	  expression	  during	  human	  embryogenesis	   29	  
6.2	   Identification	  of	  miRNA-­‐mRNA	  regulatory	  network	   33	  
6.3	   Perturbation	  of	  miRNA-­‐mRNA	  regulatory	  network	  during	  DS	  embryogenesis	  
	   	   39	  
6.4	   The	  role	  of	  HUNK	  as	  a	  ceRNA	   43	  
  ii 
7	   Discussion	   50	  
8	   References	   53	  
  
  iii 
Table of Figures 
Figure 1: Trisomy 21 karyotype showing three copies of human chromosome 
21 (HSA21) 5 
Figure 2: HSA21 conserved synteny with mouse chromosomes Mmu10, 
Mmu16 and Mmu17 9 
Figure 3: Hypothesis for Trisomy 21 phenotypes 12 
Figure 4: RNAs' crosstalk mediated by miRNAs 13 
Figure 5: miRNA biogenesis 15 
Figure 6: Mechanisms of miRNA-mediated silencing 18 
Figure 7: mRNA expression during weeks 4-6 of human development 30 
Figure 8: Statistical over-representation test of 11080 expressed genes during 
weeks 4-6 of development, according to Panther GO-Slim Biological Process 31 
Figure 9: Top 15 mRNAs expression levels during weeks 4-6 of human 
development 31 
Figure 10: miRNA expression during weeks 4-6 of human development 32 
Figure 11: Top 15 miRNAs expression levels during weeks 4-6 of human 
development 33 
Figure 12: Correlation distribution curve before (green) and after (red) 
integration of prediction of miRNA-mRNA interactions 34 
Figure 13: Bubbleplot representing biclustering results 36 
Figure 14: Heatmap of the extracted bicluster 37 
Figure 15: Correlation distribution curve for the extracted bicluster 38 
Figure 16: Biological processes over-representation of 210 genes of the 
selected bicluster 39 
Figure 17: Per base read quality 40 
Figure 18: Per sequence read quality 40 
Figure 19: Box plot of RPKM counts distribution 41 
Figure 20: PCA plot of euploid and DS samples before (upper) and after 
(lower) removing EU2 sample (red arrow). 42 
Figure 21: HUNK expression 24, 30, 48 hours after HUNK 3'UTR transfection
 45 
  iv 
Figure 22: Gene expression after HUNK 3'UTR transfection 46 
Figure 23: miRNA expression in HEK293 cells 24 and 30 hours after HUNK 
3'UTR transfection 47 
Figure 24: Expression analysis of selected genes 24h after transfection of 
partial HUNK 3'UTR fragments 48 
Figure 25: Expression analysis of selected miRNAs 24h after transfection of 
partial HUNK 3'UTR fragments 49 
 
 1 
1 Abstract (Italiano) 
La sindrome di Down (DS), la cui causa genetica fu ricondotta alla trisomia 
completa o parziale del cromosoma 21 (HSA21), è la più comune aneuploidia 
umana compatibile con la vita. La DS è una complessa condizione genetica 
caratterizzata da più di 80 diversi fenotipi clinici, con espressività e penetranza 
estremamente variabili. Gli individui affetti da DS presentano alterazioni - sia di 
carattere strutturale sia funzionale - a carico di differenti organi e sistemi, che 
lasciano presupporre un’alterazione dell’embriogenesi negli individui affetti da 
sindrome di Down, dovuta alla Trisomia 21. L'alterazione del quadro fenotipico 
in individui con la sindrome di Down è stata attribuita in primo luogo ad 
anomalie nel dosaggio genico, derivanti dalla trisomia del cromosoma 21. 
Tuttavia, studi di espressione genica eseguiti su larga scala hanno messo in 
luce uno scenario più complesso, in cui si assiste a una deregolazione 
trascrizionale globale, estesa ai geni euploidi. In tale contesto, è ipotizzabile 
l’esistenza di un meccanismo di controllo dell’espressione genica più 
complesso, che presuppone interazioni dirette e/o indirette tra i prodotti genici 
del cromosoma 21 e i geni localizzati sugli altri cromosomi. Inoltre, 
recentemente è emerso un cross-talk tra RNA messaggeri, pseudogeni e 
lincRNA, mediato dalla competizione per il legame a specifici miRNA. Pertanto, 
lo sbilanciamento genico dovuto alla trisomia del cromosoma 21, potrebbe agire 
sull’espressione genica globale, mediante un cross-talk mediato dall’interazione 
con specifici miRNA durante l’embriogenesi, causando alterazioni dello sviluppo 
e determinando, conseguentemente, il carattere multisistemico tipico del 
fenotipo della sindrome di Down.  
Alla luce di tali evidenze, lo scopo di questo progetto di dottorato si è focalizzato 
sullo studio della deregolazione genica globale e del potenziale ruolo di 
“spugne” di microRNA svolto dai geni HSA21 sovraespressi nella sindrome 
durante lo sviluppo embrionale.  
L’analisi di dataset pubblici di espressione di miRNA e mRNA condotti su 
embrioni umani alla 4-6 settimana di sviluppo ha permesso di delineare un 
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network di interazione miRNA/mRNA durante l’embriogenesi. Inoltre, tale studio 
ha mostrato che la sovraespressione del 3’UTR del gene HSA21 HUNK, 
sovraespresso nella sindrome di Down, induce un aumento dell’espressione di 
geni coinvolti nello sviluppo embrionale, tra cui BCL2, CLIC5, EPHA5, ERBB4, 
HIPK2, MECP2, ONECUT2, e WNT5A, ed una riduzione dell’espressione di 
miRNA, tra cui miR-17, miR-20a, miR-20b, miR-128 e miR-200c. Tali risultati 
suggeriscono che ci siano perturbazioni del normale network di regolazione tra 
mRNA e miRNA durante lo sviluppo di embrioni affetti da DS, causate dalla 
sovraespressione dei geni HSA21 presenti in triplice copia. Ciò spiegherebbe, 
almeno in parte, le alterazioni a carattere multisistemico tipiche della sindrome. 
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2 Abstract (English) 
Down syndrome (DS) - also known as Trisomy 21 - is a genetic disorder caused 
by an extra copy of all or part of human chromosome 21 (HSA21). DS is a 
complex genetic condition characterized by over 80 clinically different 
phenotypes of variable penetrance and expressivity. Individuals with DS show 
alterations - both structural and functional - affecting distinct organs and 
systems, which suggest that a perturbation of embryogenesis occurs in 
individuals with Down syndrome, due to Trisomy 21.  
Large-scale gene expression studies have revealed a more complex scenario, 
highlighting a global transcriptional deregulation, extended also to genes 
mapping outside the DS Critical Region (DSCR) on HSA21, as well as on the 
other chromosomes. In this context, it is clear that direct and/or indirect 
interactions between gene products of HSA21 and those from the other 
chromosomes can better explain the complexity of the clinical manifestations of 
the disorder. Recent studies have pointed out a previously unexpected role of 
non-coding RNA (ncRNAs), such as pseudogenes and lincRNAs, on gene 
expression regulation. In particular, a new crosstalk mediated by the 
competition for the binding to specific miRNAs has been demonstrated between 
messenger RNAs and ncRNAs. Such a regulatory crosstalk represents a new 
and interesting "RNA language" through which different mRNAs regulate each 
other by competing for miRNAs' availability.  
Given these recent findings and considering that Trisomy 21-induced gene 
imbalance perturbs the entire transcriptome and occurs throughout the 
embryogenesis, the above-described regulatory crosstalk may be altered by 
HSA21 trisomy in DS foetuses. The pathological overexpression of HSA21 
genes may perturb gene expression during embryogenesis through the 
alteration of the crosstalk mediated by the interaction with specific miRNAs. In 
turn, it would cause typical multisystem clinical manifestations of Down 
syndrome. 
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Thus, the aim of this PhD project is to deeply explore the global gene 
deregulation, and the potential role of microRNAs' "sponges" played by HSA21 
genes that are overexpressed in DS during embryonic development. Taking 
advantage of publicly available mRNA and miRNA expression datasets of 
human embryos (4-6 weeks), a regulatory miRNA/mRNA network in these 
crucial weeks of the human embryonic development was established. A 
significant fraction of genes within the network belong to developmental-related 
pathways. Afterwards, HSA21 genes overexpressed in DS embryos that belong 
to this network were identified using RNA-Seq datasets from DS and euploid 
matched chorionic villi. HUNK gene was computationally selected as the best 
candidate to be an HSA21-derived miRNAs’ sponge. Experimental studies 
confirmed that the overexpression of its 3'UTR induces an increased expression 
of genes involved in embryonic development, including BCL2, CLIC5, EPHA5, 
ERBB4, HIPK2, MECP2, ONECUT2, and WNT5A, and a reduction of the 
expression of correlated miRNAs, including miR-17, miR-20a, miR-20b, miR-
128 and miR-200c. Although further studies are still in progress, the results of 
both the computational and the experimental studies strongly suggest that the 
overexpression of HSA21 genes may perturb the physiologic regulatory 
miRNA/mRNA network during DS embryos' development. This would explain, at 
least in part, the multisystemic nature of the alterations that typically occur in 
individuals with the syndrome. 
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3 Introduction 
3.1 Down syndrome 
Down syndrome (DS) - also known as Trisomy 21 - is a genetic disorder caused 
by an extra copy of all or part of human chromosome 21 (HSA21; Figure 1). DS 
was first characterized as a separate form of mental disability in 1866 by John 
Langdon Down, who used the term ‘mongoloid’, due to shared facial similarities 
of children with Down syndrome with those of Mongolian race (Down, 1995). 
The term ‘Trisomy 21’ began to be addressed to DS in 1959, when Jérôme 
Lejeune reported the discovery that Down syndrome resulted from an extra 
chromosome, using karyotype technique (Lejeune et al., 1959). Trisomy 21 is 
the most frequent human aneuploidy with an incidence of 1 in every 700-800 
live births in Western countries (Park and Chung, 2013).  
 
 
Figure 1: Trisomy 21 karyotype showing three copies of human chromosome 21 (HSA21) 
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3.1.1 Down syndrome as a multisystem disorder 
DS is a complex genetic condition characterized by over 80 clinically different 
phenotypes of variable penetrance and expressivity. Individuals with DS show 
alterations - both structural and functional - affecting distinct organs and 
systems, which generally evolve with age (Antonarakis and Epstein, 2006). 
Physical growth delays, distinguishing dysmorphic features - especially visible 
in the craniofacies, hands and feet - muscle hypotonia, and mild to moderate 
intellectual disability represent constant features observed in DS. Individuals 
with DS present an increased risk of early-onset Alzheimer-like 
neurodegeneration (Reeves et al., 2001; Wiseman et al., 2009). Two groups of 
major congenital abnormalities, that can cause morbidity or even death if left 
untreated, are associated with DS: congenital heart disease (CHD) and several 
types of gastrointestinal-tract obstruction or dysfunction. CHD affect 
approximately 50% of children with DS, with a wide range of defects and 
severity. Atrial or ventricular septal defect, complete atrioventricular-canal 
defect, mitral valve problems, tetralogy of Fallot and patent ductus arteriosus 
are common features of DS heart (Antonarakis and Epstein, 2006; Wiseman et 
al., 2009). The gastrointestinal system is also affected, particularly duodenal 
stenosis or atresia, pyloric stenosis, Meckel diverticulum, imperforate anus and 
Hirschprung disease occur with an increased incidence in DS children 
(Patterson, 2007). Moreover, defects involving the immune and haematopoietic 
systems are recurrent phenomena in the pathogenesis of the syndrome. 
Individuals with Down syndrome have a 20-fold increased risk of childhood 
acute lymphoblastic leukaemia (ALL) and a decreased risk of solid tumours, 
such as breast cancer, in all age-groups (Patterson, 2009). These evidences, 
combined to the reduced incidence of diabetic proliferative retinopathy and 
atherosclerosis, strongly indicate a suppression of angiogenesis (Ryeom and 
Folkman, 2009).  
Introduction 
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3.1.2 Embryogenesis and Down syndrome 
The multisystemic nature of DS phenotype suggests that Trisomy 21 has a 
significant impact on the development and differentiation of several organs and 
tissues. It is reasonable that the presence of three copies of HSA21 genes in 
the early stages of DS embryonic development determine alterations of 
organogenesis. Experimental approaches to elucidate the mechanisms by 
which aneuploidy affects development represent a considerable challenge. 
Since systematic studies of embryonic and fetal development are difficult in 
human, mouse models and embryonic stem (ES) cells have been used to study 
the role of mammalian aneuploidy in developmental processes. Many genetic 
pathways regulating development are affected in similar ways in DS and DS 
mouse model (Baxter et al., 2000). Several evidences have revealed that 
Trisomy 21 affects development of brain, neuronal synapses, cerebellum, 
neurocranium, heart, mandible, and eye. Indeed, delays in neocortical 
development and delays in prenatal growth of cerebral cortex and 
hippocampus, due to reduced neurogenesis from the ventricular zone neural 
precursor population, were found in DS mouse models (Chakrabarti et al., 
2007). Moreover, cerebellar volume is significantly reduced in Ts65Dn mice - 
due to reduction of both the internal granule layer and the molecular layer of the 
cerebellum - and craniofacial abnormalities are seen in DS and in the Ts65Dn 
and Ts1Cje mouse models (Baxter et al., 2000; Richtsmeier et al., 2002). 
Regarding the heart development, abnormal ventricular septation, representing 
a failure of fusion between the ventricular septum and the proximal outflow tract 
cushions, was seen in Tc1 mice (O’Doherty et al., 2005).  
3.1.3 Chromosome 21 and gene expression 
DS pathological features are considered to be a direct consequence of the 
dosage imbalance, and in turn of gene expression levels alterations, of genes 
located on chromosome 21. However, several genetic factors, such as different 
allele combinations of HSA21 genes, and environmental influences are likely to 
contribute to individual variability in DS. 
Introduction 
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The phenotypic alterations occurring in individuals affected with DS was 
primarily attributed to gene dosage imbalance resulting from the presence of an 
extra copy of chromosome 21. Thus, characterization of all HSA21 genes 
represented a starting point to better understand the molecular mechanisms 
underlying the different phenotypic manifestations of the DS.  
Human chromosome 21 is the smallest acrocentric chromosome and 
represents 1.5% of the entire human genome, spanning about 50 million base 
pairs. The almost complete, high-quality sequence of the long arm (21q) of 
HSA21 was published in 2000 (Hattori et al., 2000). The initial analysis of 21q 
revealed 225 genes (127 known genes and 98 putative novel genes predicted 
in silico) and 59 pseudogenes (Hattori et al., 2000). Although the precise gene 
catalogue has not yet been conclusively determined, the total number of HSA21 
genes has increased to more than 350 (Gardiner, 2003). Several studies have 
been focused to find out specific genotype-phenotype correlations, through the 
characterization of chromosome 21 genes functions and the consequences of 
their increased expression to specific features of the phenotype, according to a 
‘gene dosage’ hypothesis. Such hypothesis states that specific phenotypes are 
a consequence of a gene dosage imbalance that results in overexpression of 
individual causative genes. To address this issue, human partial trisomy and 
DS mouse models have been studied (Lyle et al., 2009). Mapping partial 
HSA21 trisomy allowed narrowing studies to a limited region of chromosome 
21, called “Down Syndrome Critical Region” (DSCR), that contains genes 
responsible for many features of DS (Barlow et al., 2001; Korenberg et al., 
1990; Sinet et al., 1994). The DSCR was defined with a proximal boundary 
between markers D21S17 (35 892 kb) and D21S55 (38 012 kb), and a distal 
boundary at MX1 (41 720 kb). This is a region spanning 3.8–6.5 Mb and 
containing 25–50 genes. Although the notion of a DSCR has gained some 
acceptance in DS research, the data supporting it remain controversial. The 
generation of several DS mouse models enabled further progress in the 
research for dosage-sensitive genes underlying DS. HSA21 shares conserved 
Introduction 
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synteny with orthologous regions on three mouse chromosomes: Mmu10, 
Mmu16 and Mmu17 (Figure 2).  
 
 
 
Figure 2: HSA21 conserved synteny with mouse chromosomes Mmu10, Mmu16 and Mmu17 
The first two models that were generated, Ts65Dn and Ts1Cje mice, with 
duplications of parts of Mmu16, showed several morphological and functional 
features of DS. In particular, it was demonstrated that some DSCR genes are 
involved in development of different organs and tissues. Indeed, the presence 
of three copies of the DYRK1A gene is related to learning, memory and brain 
development, neurodegeneration, and motor control, while DSCAM gene is 
associated to cardiac defects and ETS2 and ERG genes are involved in 
leukaemia (Lana-elola et al., 2011).  
However, the strategy to map partial trisomy 21 in animal models or to analyze 
by microarray the gene expression in different DS cells/tissues, have often 
reported conflicting results (Diller et al., 2008; Jablonska et al., 2006; Li et al., 
2006; Lyle et al., 2009; Sommer and Henrique-Silva, 2008). Indeed, a study on 
a mouse model either trisomic or monosomic for the syntenic DSCR found that 
trisomy for the DSCR alone is not sufficient to produce the structural and 
Baxter et al., 2000 
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functional brain phenotypes (Olson et al., 2007). These accumulating evidences 
highlight a more complex scenario, suggesting fundamental pieces of the Down 
syndrome genotype-phenotype jigsaw puzzle are still missing. 
 
3.2 Beyond the gene dosage hypothesis 
The simplest model for levels of gene expression in DS would predict that each 
gene on chromosome 21 would be expressed at 150% with respect to 
expression levels in euploid individuals. Thus, gene-expression differences 
between euploid and trisomy 21 cells and tissues have been studied by 
microarrays, serial analysis of gene expression (SAGE) methodology, 
differential display PCR, or Real-Time quantitative PCR (FitzPatrick et al., 2002; 
Kahlem et al., 2004; Lyle et al., 2004; Mao et al., 2003; Saran et al., 2003). 
Such studies have often reported conflicting results. Indeed, several studies 
showed that only 37% of genes in various DS tissues were expressed at the 
theoretical level of 1.5-fold relative to euploid. Therefore, HSA21 genes could 
show an expression level different from the expected 1.5 fold, implying the 
existence of a compensation mechanism of gene dosage (Kahlem et al., 2004; 
Lyle et al., 2004).  
Moreover, large-scale gene expression studies performed on DS specimens 
have revealed a more complex scenario, highlighting a global transcriptional 
deregulation, extended to euploid genes (Costa et al., 2010, 2011; Esposito et 
al., 2008; FitzPatrick et al., 2002; Vilardell et al., 2011). Hence, although strong 
evidences suggest that the dosage imbalance of specific HSA21 genes directly 
contributes to some characteristic features of the Down syndrome, additional 
mechanisms are needed to fully explain the complexity of the manifestations 
and the global gene deregulation of the disorder. Such global mechanisms may 
include copy number variations, transcription factors alteration, conserved non-
coding regions, post-transcriptional regulation, DNA methylation and gene-gene 
interactions (Patterson, 2007). For example, at least 25 genes localized on 
chromosome 21 encodes proteins that directly or indirectly regulate gene 
Introduction 
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transcription, while other chromosome 21 proteins contribute to post-
translational modification of transcription factors, including their 
phosphorylation, dephosphorylation and sumoylation (Gardiner, 2006). Thus, 
altered stoichiometry in transcription factors’ complexes, due to extra copy of 
HSA21, may contribute to the Down syndrome phenotype, determining 
perturbation of downstream gene expression. Moreover, recent studies have 
highlighted the role of non-coding RNAs (ncRNAs) in regulation of gene 
expression. Particularly, microRNAs (miRNAs) have been shown to control 
gene expression, interfering with translation or inducing degradation of mRNA. 
Further, miRNAs have been identified in all tissues in mammals and have been 
associated with several biological processes, including development and 
differentiation (Motti et al., 2012). Since each miRNA may regulate expression 
of hundreds mRNAs and five miRNAs (i.e., miR-99a, let-7c, miR-125b-2, miR-
155 and miR-802) are encoded by genes on HSA21, it is reasonable that 
HSA21‑derived miRNAs could control expression of other genes. Indeed, 
HSA21‑derived micro-RNAs are overexpressed in Down syndrome brain and 
heart specimens, leading to improper repression of specific target proteins that 
are linked to specific phenotypes (Dierssen, 2012). 
In conclusion, overexpression of individual genes cannot be considered 
independently when one considers phenotype–genotype correlations. Indeed, 
global gene deregulation suggests a more complex mechanism of gene 
expression regulation, which involves direct and/or indirect interactions among 
HSA21 gene products and genes located on the other chromosomes (Figure 3). 
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Figure 3: Hypothesis for Trisomy 21 phenotypes 
 
3.2.1 ceRNA hypothesis 
Recently, several evidences have shown cross-talk between RNAs, both coding 
and non-coding, through microRNA binding, which determine large-scale 
regulatory network across the transcriptome (Poliseno et al., 2010; Salmena et 
al., 2011; Tay et al., 2011). RNAs influence each other’s levels by competing for 
a limited pool of miRNAs. This competing endogenous RNAs (ceRNAs) act as 
miRNAs “sponges” by sharing common microRNA responsive elements 
(MREs), inhibiting normal miRNAs activity. These sponges absorb miRNAs, 
lowering the levels of available miRNAs for the target mRNA, resulting in 
increased translations (Figure 4).  
 
Antonarakis et al., 2004 
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Figure 4: RNAs' crosstalk mediated by miRNAs 
 
This new “RNA language” mediated by MREs regulates gene expression in 
several biological processes, including development and differentiation. Thus, 
ceRNA activity explains the complexity of organisms’ transcriptome landscape.  
Moreover, perturbations of ceRNAs and ceRNA networks could have an impact 
on disease onset. Indeed, ceRNAs have been shown to be involved in the 
pathogenesis of several common cancers such as melanoma, prostate cancer, 
liver cancer, breast cancer, and thyroid cancer (Fan et al., 2013; Kumar et al., 
2014; Tay et al., 2011, 2014).  
3.3 microRNAs 
In the past ten years, genome-wide expression analyses have revealed a 
pervasive transcription of human genome, bringing to light thousands of non-
coding transcripts. These evidences determined a revolution in the “RNA 
world”, leading to reconsider the central dogma of biology (Mattick and 
Makunin, 2006). Further studies have revealed that ncRNAs represents an 
Salmena et al., 2010 
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hidden layer of molecular genetics, which fulfill a wide range of functions, 
including the control of chromosome dynamics, splicing, RNA editing, 
translational inhibition and mRNA destruction (Eddy, 2001).  
A class of ncRNAs is represented by microRNAs, which are short (22 
nucleotide in length) endogenous non-coding RNAs involved in gene 
expression regulation in plant and animals. The first miRNA, lin-4, was 
discovered in 1993 in C. elegans. lin-4 gene did not encode a protein, but it 
produced a short non-coding RNA complementary to multiple sequences in the 
3' UTR of the lin-14 gene, which control the timing of larval development by 
repressing lin-14 (Lee et al., 1993). Nevertheless, only a few years later, the 
characterization of a second small ncRNA, let-7, highlighted the hidden role of 
miRNAs regulation (Reinhart et al., 2000). 
miRNAs influence gene expression by sequence-specific binding to target 
mRNAs and promoting their degradation and/or translational inhibition (Bartel, 
2004). miRNAs have been shown to play a crucial regulatory role in several 
biological processes, including developmental transitions, neuronal patterning, 
apoptosis, adipogenesis metabolism and hematopoiesis. Moreover, altered 
levels of miRNAs’ expression have been associated with the pathogenesis of 
different human diseases, such as cancer, cardiovascular disorders, Alzheimer 
disease, viral infections and metabolic diseases (Singh et al., 2008). 
3.3.1 miRNA biogenesis 
Most miRNA genes are transcribed by RNA polymerase II into a long primary 
transcript (pri-miRNA) with a local hairpin structure containing miRNA precursor, 
pre-miRNA (Ha and Kim, 2014); Figure 5).  
Introduction 
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Figure 5: miRNA biogenesis 
 
Pri-miRNA can range in size from hundreds of nucleotides to tens of kilobases 
(Bushati and Cohen, 2007). However, miRNAs can also be transcribed by RNA 
polymerase III, which specifically synthesizes small non-protein coding RNAs, 
such as tRNAs, 5S ribosomal RNA, and the U6 snRNA (Bartel, 2004). Most 
mammalian miRNAs are intergenic or are encoded by introns of both coding 
and non-coding genes, while some miRNAs are encoded by exonic regions. 
Intronic miRNAs’ processing does not affect splicing of the host pre-mRNA and 
appears to occur co-transcriptionally before splicing catalysis (Kim et al., 2007).  
The pre-miRNA hairpin is processed from the pri-miRNA transcript within the 
nucleus by a multiprotein complex called the Microprocessor. The core of this 
complex consists of the RNase III enzyme Drosha and the double-stranded 
RNA-binding domain (dsRBD) protein known as DiGeorge syndrome critical 
region 8 (DGCR8 or "Pasha" in invertebrates) (Ha and Kim, 2014). DGCR8 
recognizes the pri-miRNA at the junction of single stranded RNA and double 
Winter et al., 2009 
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stranded RNA and guides the catalytic RNase III domain of Drosha to a specific 
cleavage. Drosha cleaves the pri-miRNA ~11 bp from the junction on the stem, 
producing a ~ 60-70 bp pre-miRNA with a 5’ phosphate and a two-nucleotide 3’ 
overhang (Han et al., 2006).  
Following Drosha processing, pre-miRNA is exported into the cytoplasm to 
complete maturation process. The export receptor Exportin-5 recognizes the 2-
nt 3’ overhang, characteristic of RNase III-mediated cleavage, and transports 
the pre-miRNA into the cytoplasm via a Ran-GTP-dependent mechanism (Ha 
and Kim, 2014). Once in the cytoplasm, the pre-miRNA is cleaved near the 
terminal loop by Dicer to produce the mature ~22-nt miRNA:miRNA* duplex 
(Bushati and Cohen, 2007). Dicer is another RNase III endonuclease, highly 
conserved in all eukaryotes, with a N-terminal ATPase/Helicase domain, 
DUF283 (domain of unknown function), PAZ (Piwi/Argonaute/Zwilli) domain, 
and two tandem RNase III nuclease domains (RNase IIIa and RNase IIIb) 
located at the C-terminal followed by a dsRNA-binding domain (dsRBD). The 
PAZ domain binds the 2nt 3’ overhang of pre-miRNA and the two RNase III 
domains cleave (“dice”) the dsRNA (Macfarlane and Murphy, 2010). 
Dicer, together with the human immunodeficiency virus trans-activating 
response RNA binding protein (TRBP), recruits the Argonaute protein Ago2 
(and other Ago proteins), and they form a trimeric complex that initiates the 
assembly of the RNA-induced silencing complex (RISC), a ribonucleoprotein 
complex (Bushati and Cohen, 2007). Only one strand is usually incorporated 
into RISC complex: the miRNA strand with relatively lower stability of base-
pairing at its 5’ end is incorporated into RISC, whereas the miRNA* strand is 
typically degraded. Once incorporated into RISC, the miRNA guides the 
complex to its mRNA targets for silencing mediated by base-pairing 
interactions. 
3.3.2 miRNA-mediated silencing 
miRNAs mediate mRNA silencing through physical interaction with 3’UTR 
sequence of mRNA. Target silencing may occur either via mRNA degradation 
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or preventing mRNA translation, depending on the identity of base pairing. In 
cases of perfect complementarity to the miRNA, target mRNAs undergo 
degradation; otherwise, their translation is prevented (Bushati and Cohen, 
2007). miRNAs mediate mRNA repression by recruiting the RISC complex to 
target mRNAs. Argonaute proteins, specifically Ago2 in mammals and flies, are 
capable of endonucleolytic cleavage and are essential for miRNA-mediated 
gene silencing (Bushati and Cohen, 2007; Fabian and Sonenberg, 2012). Ago 
proteins interact with GW182/TNRC6 (TriNucleotide repeat-containing) family 
proteins, which provide a platform for interaction with several proteins and 
complexes required for miRNA target decay (Fabian and Sonenberg, 2012). 
First, interaction with poly(A) binding protein (PABP), and CCR4-NOT and 
PAN2-PAN3 deadenylase complexes, induces target deadenylation of the 
poly(A) tail. Following deadenylation, DCP1-DCP2 decapping complexes 
remove the 5’ terminal cap and the target mRNA is degraded by Xrn1 5’-3’ 
exonuclease (Fabian and Sonenberg, 2012; Inada and Makino, 2014). 
Imperfect base-pairing of miRNAs with their targets promotes translational 
repression rather than cleavage and degradation. The mechanism of 
translational repression by miRNAs remains controversial. Some studies show 
that miRNAs block translation initiation, whereas other studies suggest a block 
in elongation (Bushati and Cohen, 2007). A recent model suggests that during 
miRNA-mediated repression all three levels of translation (initiation, elongation 
and termination) are coordinately inhibited or slowed (Gu and Kay, 2010); 
Figure 6).  
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Figure 6: Mechanisms of miRNA-mediated silencing 
 
Indeed, RISC complex inhibits translation initiation by interfering with eIF4G cap 
recognition, by preventing the circularization required for efficient translation 
and by preventing the 60S and 40S ribosomes assembly. Moreover, miRNA-
induced silencing complex might inhibit ribosome elongation or promote 
premature translation termination and co-translation degradation in the P-
bodies (Bushati and Cohen, 2007; Gu and Kay, 2010). 
 
Sethi et al., 2013 
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4 Aim 
The multisystemic nature of Down syndrome suggests the involvement of 
chromosome 21 trisomy in the development and differentiation of different 
organs and tissues (Wiseman et al., 2009). However, the role of triplicated 
genes and the mechanism by which they alter the events underlying 
organogenesis are still unclear. Thus, addressing the pathogenic mechanisms 
underlying the Down syndrome in the early stages of embryonic development, 
when organogenesis occurs, is of crucial relevance. Moreover, large-scale gene 
expression studies on Down syndrome cells/tissue – carried out also in our 
laboratory (Costa et al., 2010, 2011) - revealed a more complex scenario. 
Particularly, it has been shown that the transcriptional deregulation is not limited 
to genes mapping on HSA21, but it is extended to euploid genes, suggesting 
direct and/or indirect interactions between HSA21 genes and genes located on 
other chromosomes. Furthermore, very recently, the existence - at least in 
tumours - of a new gene regulatory mechanism based on the competition for 
microRNAs binding (the competing endogenous RNAs, ceRNAs) has been 
demonstrated. 
In light of these considerations, the aim of my PhD project is to understand 
whether the multisystemic alterations of Down syndrome can be caused, at 
least in part, by a competition for the same miRNAs between HSA21 and non-
HSA21 transcripts in early stages of the embryonic development. The main 
purpose of this project is to assess whether HSA21 mRNAs - that are 
overexpressed in DS embryos - can potentially function as miRNA "sponges", 
acting as ceRNAs and thus perturbing the expression of non-HSA21 mRNAs 
involved in the organogenesis. 
The starting hypothesis is that the presence - throughout the entire embryonic 
development - of supernumerary copies of HSA21 mRNAs in DS embryos may 
disrupt the physiological mRNAs/miRNAs balance. It would affect the miRNA-
mediated gene silencing that physiologically occurs during the embryonic 
development. This hypothesis would explain - at least partially - the 
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multisystemic nature of the DS pathological outcomes, the heterogeneous 
phenotype of DS individuals as well as the global gene expression deregulation 
observed in distinct cell types and tissues isolated from DS individuals. 
To address this aim, my PhD project first focused on the definition of a network 
of potential interactions between HSA21 and non-HSA21 genes mediated by 
miRNAs' binding during the early stages of human embryonic development. 
Such network is built on mRNAs and miRNAs expression data collected at 
specific weeks of the embryogenesis, and is based on a computational 
prediction analysis of miRNA binding sites within 3'UTRs of all the expressed 
genes. Then, the research project focused on the potential perturbation of such 
network - in DS embryos - induced by the presence of supernumerary copy of 
HSA21 genes. Afterwards, the computationally predicted mRNA/miRNAs 
interactions were evaluated using experimental in vitro approaches to validate 
the potential role of a selected HSA21 gene (i.e. HUNK) as sponge for miRNAs. 
The aim of the project was also to establish a potential regulatory crosstalk 
between HSA21 genes and those belonging to development- and embryo-
related pathways. The hypothesis is that such mRNAs may reciprocally regulate 
their expression through a ceRNA (or ceRNA-like) network. 
As stated in the seminal work of Salmena and colleagues (2011), the aim of this 
project is to demonstrate that HSA21 genes overexpressed in DS embryos and 
some developmentally relevant mRNAs "talk to each other using microRNA 
response elements, as letters of a new language". 
 
 
Methods 
 21 
5 Methods 
5.1 Data processing and bioinformatics analysis 
5.1.1 Expression data sets description and processing 
To assess gene expression for mRNAs and miRNAs during human 
embryogenesis, two previously published data sets were analysed. For mRNAs 
expression, a microarray genome-wide expression study carried out on human 
embryos during weeks 4-9 of development was analysed (Yi et al., 2010). 
Microarray technology involves the hybridization of mRNA molecules to probes 
immobilized in known locations on a chip. Fluorescence signal intensity of each 
spot is detected as an indirect measure of a specific gene expression. This 
study was performed on three RNA samples from whole embryo for each week 
using the Human Genome U133 Plus 2.0 Array (Affymetrix), which contains 
50093 transcripts accounting for 38500 human genes. Normalized mRNA 
expression data were retrieved from the public functional genomics data 
repository Gene Expression Omnibus (GEO) at the National Center of 
Biotechnology Information (NCBI), through Geo Series accession number 
GSE15744. Custom MATLAB scripts were used to process data. Particularly, 
probe set IDs were associated to corresponding gene symbols using the HG-
U133A_2 Affymetrix annotation file and mean values were calculated across 
genes. After filtering out mean values among replicates inferior than an arbitrary 
threshold of 49.5 signal intensity, an mRNA expression matrix was compiled for 
weeks 4-6 of human embryogenesis. 
For miRNAs expression, a recently published miRNA microarray study was 
analysed (Lin et al., 2013). The miRNA expression study was performed on 
small RNA samples extracted from 3 embryos at week 4, 3 embryos at week 5 
and 2 embryos at week 6 of development in dual-sample experiments, using 
µParaflo microfluidic chip (Atactic Technologies), which covers 835 miRNAs 
annotated in the Sanger miRBase database (release 10.1). Normalized miRNA 
expression data were retrieved from GEO through Geo Series accession 
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number GSE46795. MATLAB scripts were used to calculate mean values 
among replicates and to set an arbitrary threshold of 49.5 signal intensity in 
order to compile a matrix for miRNA expression during human embryogenesis.  
Using a custom MATLAB script, Pearson’s linear correlation was calculated 
between each mRNA-miRNA pair after logarithmic transformation of expression 
data and a 2D correlation matrix was compiled.  
5.1.2 mRNA-miRNA interactions prediction 
Fasta file corresponding to the 3’UTR sequences of 11080 genes expressed 
during weeks 4-6 of human development were downloaded from UCSC Table 
Browser (Karolchik et al., 2004). MREs in these sequences were predicted 
executing TargetScan 6.0 algorithm implemented in Perl language. Target 
prediction data were filtered out to remove miRNAs not expressed in weeks 4-6 
of human embryogenesis. Then, a binary matrix with 11080 rows and 134 
columns was compiled according to MREs prediction, and 0 and 1 were used to 
indicate the absence and presence of miRNA/mRNA interaction, respectively. 
5.1.3 Data integration and biclustering analysis 
TargetScan prediction information was integrated with the expression 
correlation data using element-by-element product of the two matrices in 
MATLAB. The integrated association matrix thus compiled underwent 
biclustering analysis. PLAID model biclustering was performed with the R 
“biclust” package (Turner et al., 2005). This algorithm is an improvement of 
original ’Plaid Models for Gene Expression Data’ (Lazzeroni and Owen, 2002). 
The plaid model allows a gene to be in more than one cluster, or in none at all. 
It consists of a series of additive layers intended to capture the underlying 
structure of a gene expression matrix. Each layer is fitted to linear model y ~ m 
+ a + b, that estimates three parameters: m (constant for all elements in the 
bicluster), a (constant for all rows in the bicluster) and b (constant for all 
columns).  
For the biclustering analysis, background layer was considered absent in the 
data matrix. Before a layer is added, it’s statistical significance is compared 
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against 3 layers obtained by random, 15 and 10 iterations were performed to 
find starting values and each layer, respectively. The row and column release 
probabilities were set to 0.6 and the maximum number of layers to 50. The 
biclustering algorithm was iterated 100 times. 
5.1.4 Differential gene expression in DS embryos 
RNA-Sequencing data sets from 5 normal and 4 DS chorionic villus samples 
were downloaded from GEO (accession n. GSE42144) in SRA format and then 
converted into FASTQ format using fastq-dump function included in the SRA 
Toolkit. Reads quality was evaluated through the FASTQC software. RNA-Seq 
reads were mapped against human reference transcriptome and then genome 
hg19 using TopHat v.2 software, allowing 3 segment mismatch. Gene counts 
and RPKM (Reads Per Kilobase of transcript per Million mapped reads) 
normalization were performed using RNASeqGUI R package (Russo and 
Angelini, 2014) and a threshold of 1 RPKM was used. Average RPKM values 
for each gene in each sample group (euploid and DS) were calculated. To 
identify differentially expressed genes in DS versus euploid conditions, fold 
change (FC) was calculated as the ratio of average RPKM value for 
DS/average RPKM value for euploid. Genes with a FC equal or greater than 1.5 
FC were considered up-regulated in DS.  
5.2 Generation of plasmid constructs 
The full 3’UTR of HUNK gene (NM_014586) and the five partially overlapping 
3’UTR fragments of the same 3'UTR were amplified from cDNA of MCF7 cell 
line by polymerase chain reaction (PCR). Specific PCR primers were designed 
using Oligo 4.0 software and synthesized by IDT (Table 1).  
PCR reactions were carried out in 25 µL reaction volume, using 1 unit of 
Platinum Taq DNA Polymerase High Fidelity (Invitrogen), 2.5 µL of 10X High 
Fidelity PCR Buffer, 1 µL of MgSO4 (50 mM), 0.5 µL of dNTP mix (10 mM), 0.7 
µL of each primer (8 µM) and 1 µL of cDNA (50 ng/µL). Amplification was 
performed in Bio-Rad thermal cycler under the following conditions: 94°C for 1 
min; then 35 cycles of 94°C for 30 sec, annealing temperature (Ta) for 30 sec, 
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68°C for 6 min; and a final extension at 68°C for 30 min. Amplicons were 
analysed by 1.2% agarose gel electrophoresis and then underwent automated 
Sanger sequencing. 
 
Amplicon Forward Reverse 
Size 
(bp) 
Ta 
(°C) 
HUNK_3UTR_FULL CAGCGGGGTTTGGGGTAT GCTTCCTGTGCCATCTTTA 4831 60 
HUNK_3UTR_FR_1 CAGCGGGGTTTGGGGTAT TTGAAATCAGCATCGCACAG 1033 60 
HUNK_3UTR_FR_2 AGAGGGAAAAGATGATTGTGA GGAAGTACCCCTGCTCTCA 1339 57 
HUNK_3UTR_FR_3 CTTGCTGGAACCCCTGATG CTTGTTTCCAGTCAGATGCTA 996 56 
HUNK_3UTR_FR_4 TTCCCTCACTACGACTGCT GACATCCCCCTCTGACCAT 1153 56 
HUNK_3UTR_FR_5 CTCCCTCAAAGAACACAGA GCTTCCTGTGCCATCTTTA 934 58 
Table 1: Primer pairs used for HUNK 3'UTR amplification 
 
PCR products were cloned into pcDNA3.1/V5-His TOPO TA expression vector 
(Invitrogen). Particularly, 4 µL of PCR product was mixed with 1 µL of vector 
and 1 µL of salt solution (1.2 M NaCl, 0.06 M MgCl2) and incubated at room 
temperature for 20 min. Subsequently, cloning reaction mix was used to 
transform 50 µL chemically competent E. coli DH5α. Cells were incubated 30 
min in ice and then heat-shocked 1 min at 42°C. After a 1 hour incubation in 
SOC medium (2% tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 
mM MgCl2, 10 mM MgSO4, and 20 mM glucose) at 37°C in a shaking incubator 
(200 rpm), two different volumes (100 and 200 µL) of cells were spread on 
selective LB agar (1% tryptone, 0.5% yeast extract, 1% NaCl, 1.5% agar) plates 
containing 100 µg/mL ampicillin and incubated at 37°C overnight. The following 
day, 10 colonies were picked and cultured in 5 mL LB medium (1% tryptone, 
0.5% yeast extract, 1% NaCl) containing 100 µg/mL ampicillin overnight. 
Plasmid DNA was isolated from bacterial cells with the ISOLATE II Plasmid Mini 
Kit (Bioline), according to manufacturers’ instructions. Isolated plasmids were 
digested with KpnI restriction enzyme to analyse insert presence and 
orientation. Plasmids with the correct insert were sequenced. 
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5.3 Cell culture and transfection 
Human Embryonic Kidney 293 (HEK293) cell line was cultured in Dulbecco’s 
modified Eagle’s medium (DMEM, Gibco) supplemented with 10% fetal bovine 
serum (FBS, Gibco), 2  mmol/L glutamine (Gibco), 100 units/mL penicillin 
(Gibco), and 100 units/mL streptomycin (Gibco) for 4-5 passages after thawing. 
Cultures were maintained in a humidified atmosphere and 5% CO2 at 37°C.  
Cells were dissociated using Trypsin-EDTA (0.05%), phenol red (Gibco) and 
seeded in six-wells plates at 5.0x105 cells/well in 2 mL of complete medium 18h 
before transfection to ensure 70-90% confluence on the day of transfection. 
Plasmid transient transfection was performed with Lipofectamine 3000 Reagent 
(Invitrogen), using a 1:3 DNA:lipid ratio, according to manufacturer’s 
instructions. Particularly, 2 µg of plasmid and 6 µL of Lipofectamine 3000 were 
each diluted in 125 µL Opti-MEM Reduced-Serum Medium (Gibco). 5 µL P3000 
Reagent was added to diluted DNA. Then DNA mix was added to diluted 
Lipofectamine 3000 and incubated at room temperature for 5 minutes in order 
to allow DNA-lipid complex formation. Subsequently, 250 µL of the DNA-lipid 
complex was added dropwise to cells in serum- and antibiotic-free medium. The 
same quantity of empty pcDNA3.1 V5/His TOPO plasmid with the same lipid-to-
DNA ratio was used as the control. Cells were incubated at 37°C in a humidified 
atmosphere with 5% CO2. 6 hours after transfection, transfection mixture was 
replaced with complete medium. Transfected cells were harvested 24, 32 and 
48 hours after transfection.  
5.4 RNA extraction and Reverse Transcription 
Total RNA was isolated from HEK293 cells using mirVana miRNA Isolation kit 
(Ambion), according to manufacturer’s instructions. This kit combines the 
advantages of organic extraction and solid-phase extraction to isolate RNA 
avoiding the loss of small RNAs. The sample is first lysed in a denaturing lysis 
solution, which stabilizes RNA and inactivates RNases. The lysate is then 
extracted with Acid-Phenol:Chloroform, which removes most of the other 
cellular components, leaving a semi-pure RNA sample. This is further purified 
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over a glass-fiber filter specifically formulated for miRNA retention and finally 
the RNA is eluted with a low ionic-strength solution.  
RNA integrity and concentration were evaluated by gel electrophoresis and 
spectrophotometry (NanoDrop Technologies).  
For mRNA analysis, reverse transcription was performed on total isolated RNA 
with SUPERSCRIPT II Reverse Transcriptase (Invitrogen). Reaction mix of 1 µg 
RNA, 1 µL Oligo(dT)12-18 (500 µg/mL) and 1 µL dNTP mix (10 mM each) in a 
final volume of 12 µL was heated at 65°C for 5 min and then chilled on ice. 
Subsequently, 4 µL 5X First-Strand Buffer, 2 µL DTT (0.1 M) and 1 µL RNase 
OUT (40 units/µL) were added to the reaction mix and incubated at 42°C for 2 
min. After the addition of 1 µL of SuperScript II RT enzyme, the reaction mix 
was incubated at 42°C for 50 min and then the enzyme was inactivated heating 
the mixture at 70°C for 15 min. 
For miRNA analysis, reverse transcription was performed on total isolated RNA 
with the miSCRIPT II RT Kit (Qiagen). Reverse-transcription master mix was 
prepared with 4 µL 5X miScript HiSpec Buffer, 2 µL 10X miScript Nucleics Mix, 
2 µL miScript Reverse Transcriptase Mix and 1 µg of total RNA in a final volume 
of 20 µl. Samples were incubated at 37°C for 60 min and then at 95°C for 5 min 
to inactivate the Reverse Transcriptase Mix. 
5.5 Quantitative Real-Time PCR 
All quantitative Real-Time PCRs were performed on the CFX Connect Real-
Time PCR Detection System (Bio-Rad). For mRNA quantification, 10 µL final 
volume reaction mix was prepared using 1 µL cDNA from 1/5th of RT reaction 
with 5 µL iTaq Universal SYBR Green Supermix (Bio-Rad) and 0.4 µL of each 
primer (10 µM). After an initial polymerase activation step at 95°C for 2 min, 40 
2-steps cycles of amplification were run at 95°C for 5 sec and 60°C for 30 sec. 
Melt-curve analysis was performed from 65°C to 95°C with a 0.5°C increment 
and 5 sec/step to verify PCR product specificity. The housekeeping GAPDH 
and HPRT genes were used as reference genes for data normalization and 
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relative gene expression was measured with the 2-ΔΔCt method, comparing the 
Ct values of the samples of interest with the control.  
Mature miRNA quantification was performed using miSCRIPT SYBR Green 
PCR Kit with miSCRIPT Primer Assay (Qiagen). Reaction mix was prepared 
with 12.5 µL 2X QuantiTect SYBR Green PCR Master Mix, 2.5 µL 10X miScript 
Universal Primer, 2.5 µL miRNA-specific 10X miScript Primer Assay and 1 µL 
cDNA from 1/10th of RT reaction in 25 µL final volume. After an initial activation 
step at 95°C for 15 min, 40 cycles of amplification were run at 94°C for 15 sec, 
55°C for 30 sec and 70°C for 30 sec. Dissociation curve analysis was 
performed from 65°C to 95°C with a 0.5°C increment and 5 sec/step to assess 
the specificity of the reaction. Relative quantification was performed using the 
Ct comparison method, after data normalization with miScript PCR Controls for 
RNU6B snRNA and SNORD61 snoRNA.  
Gene specific primers used for quantitative Real-Time amplification of mRNAs 
and miRNAs are listed in Table 2 and Table 3. 
 
Gene Forward Reverse Size (bp) 
BCL2 GCCCCTGGTGGACAACATC TCAGAGACAGCCAGGAGAAAT 152 
CLIC5 ACCCGCCCTTCCTGACCTT TGCTGCTTGGTATTTTTGATG 184 
EPHA5 GGACCTGGGATGGATTGCTT TGGTTTTCCTTGATGTTTCTCC 297 
ERBB4 GAGATAACCAGCATTGAGCAC AGTTTTGTCCCACGAATAATGC 140 
HIPK2 GGAAGAGTAAGCAGCACCAG GTTCTCCTTGACACGCTTGG 107 
HUNK CAGGCTCGCTTATGACACAG GGTGGCACGGGGATGAACT 172 
MECP2 GATCAATCCCCAGGGAAAAGC CCTCTCCCAGTTACCGTGAAG 117 
ONECUT2 CCGCAGGATGTGGAAGTGG CGGGCGTTTGTTCTCCTTGA 190 
WNT5A CGCCCAGGTTGTAATTGAAG GCATGTGGTCCTGATACAAGT 164 
GAPDH GCCTCCTGCACCACCAACT CCATCACGCCACAGTTTCC 149 
HPRT TGGCGTCGTGATTAGTGATG CCCATCTCCTTCATCACATC 156 
Table 2: Primer pairs used for mRNA expression quantification by Real-Time PCR 
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miRNA Forward specific primer 
miR-17 Hs_miR-17_2 
miR-20a Hs_miR-20a_1 
miR-20b Hs_miR-20b_1 
miR-128 Hs_miR-128_1 
miR-200c Hs_miR-200c_1 
miR-205 Hs_miR-205_1 
RNU 6 Hs_RNU6-2_11 
SNORD 61 Hs_SNORD61_11 
Table 3: miRNA specific primers used in quantitative Real-Time PCR 
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6 Results 
6.1 Gene expression during human embryogenesis 
Embryogenesis is the process of cell division and differentiation that occurs 
during the early stages of embryo development, when most organs began to 
form. Mammalian development requires the specification of over 200 unique 
cell types from a single totipotent cell (Boyer et al., 2005). Human 
embryogenesis covers the first eight weeks following fertilization and is 
governed by a precise genetic program. During early and late embryo 
development, a large number of molecules participate in embryo patterning and 
organization in a spatial and temporal manner to ensure the adequate formation 
of an organism. Transcription factors and small RNAs play a crucial role in 
several developmental processes (Pauli et al., 2011). Moreover, epigenetics 
changes, including histone modification, DNA methylation, and chromatin 
condensation, regulate specific genes during embryonic development, dictating 
cell fate decisions (Barber and Rastegar, 2010).  
In this complex scenario, it is essential to understand how the global gene 
expression deregulation, due to the presence of an extra copy of chromosome 
21, may contribute to the multisystemic nature of DS phenotypes during 
embryogenesis. 
Since human embryos are difficult to access for research, publicly available 
expression datasets were downloaded and re-analysed in this PhD project to 
identify the genes expressed during human embryogenesis. Particularly, a 
Chinese research group investigated gene expression during the early stages 
of human development. They performed two independent genome-wide 
microarray studies to evaluate expression of both mRNAs and miRNAs in 
human embryos (Lin et al., 2013; Yi et al., 2010). Since miRNA expression data 
were available for weeks 4-6, expression data for mRNA were filtered out to 
remove weeks with no corresponded miRNA expression data (weeks 7-9).  
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Analysis of the mRNA microarray data showed that 11080 genes are expressed 
during weeks 4-6 of development and their number is quite constant during 
these weeks (Figure 7). 
 
Figure 7: mRNA expression during weeks 4-6 of human development 
 
Notably, statistical over-representation test performed with Panther 
Classification system showed that the 11080 genes expressed during weeks 4-
6 were involved in biological processes such as “cell cycle”, “developmental 
process”, “anatomical structure morphogenesis”, “system development” and 
“nervous system development” (Figure 8). Expressed genes were classified 
according to their expression into three main groups: a) genes with an 
increasing expression throughout weeks 4-6, b) genes with a decreasing 
expression, and c) genes with an oscillatory trend of expression during weeks 
4-6 of embryogenesis (Figure 9).  
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Figure 8: Statistical over-representation test of 11080 expressed genes during weeks 4-6 of 
development, according to Panther GO-Slim Biological Process 
 
 
 
Figure 9: Top 15 mRNAs expression levels during weeks 4-6 of human development 
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Analysis of miRNA datasets revealed that 134 out of 835 miRNAs are 
expressed during weeks 4-6 (Figure 10). These data showed that most of 
miRNAs (about 84%) are not expressed in these weeks in which organogenesis 
occurs. Similarly to the mRNAs, we could classify expressed miRNAs into three 
categories: a) miRNAs with an increasing or b) decreasing expression 
throughout weeks 4-6 and c) miRNAs with an oscillatory trend of expression 
(Figure 11).  
 
 
Figure 10: miRNA expression during weeks 4-6 of human development 
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Figure 11: Top 15 miRNAs expression levels during weeks 4-6 of human development 
 
6.2 Identification of miRNA-mRNA regulatory network 
Expression data for mRNA and miRNA were used to predict miRNA-mRNA 
interactions to define a regulatory network during early human development. 
Since miRNAs act as negative regulators of mRNAs, we were particularly 
interested in specific miRNAs with anti-correlation with the expression of its 
target mRNA. Thus, mRNA and miRNA expression data, following logarithmic 
transformations, underwent pairwise Pearson’s linear correlation analysis, in 
order to compile a 2D correlation matrix for all possible combinations of miRNA 
and mRNA expression (134 columns and 11080 rows). Pearson’s correlation 
coefficient is a degree of linear dependence between two variable and ranges 
from -1 to 1, where 1 indicates total positive correlation, 0 indicates the absence 
of correlation and -1 indicates a total negative correlation. Distribution of 
miRNA-mRNA correlation coefficients was represented by a bimodal curve with 
two distinct peaks (local maxima) at the extreme end of correlation values, 
indicating that we found a very high percentage of positive/negative miRNA-
gene associations in our analysis (Figure 12). 
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Figure 12: Correlation distribution curve before (green) and after (red) integration of prediction of 
miRNA-mRNA interactions 
 
However, these positive/negative correlations did not imply direct miRNA-
mRNA interactions. Indeed, it is known that miRNA-mRNA interactions are 
guided by sequence complementarity of the 5’ end of the miRNA, called the 
seed region, with the 3’UTR of target mRNA. MicroRNA-mRNA expression 
correlation matrix was integrated with data from the computational seed 
prediction in mRNA 3’UTR sequences of all expressed genes. Therefore, 
3’UTR sequences of 11080 genes expressed during weeks 4-6 of human 
development were downloaded from UCSC Table Browser (Karolchik et al., 
2004). MiRNA responsive elements in these sequences were predicted using 
TargetScan 6.0 algorithm implemented in Perl. Target prediction data was 
filtered out to remove miRNAs not expressed in weeks 4-6 of human 
embryogenesis. Then, a binary matrix with 11080 rows and 134 columns was 
compiled according to MREs prediction, where 0 and 1 indicate absence and 
presence of interaction, respectively. Such target prediction information was 
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integrated with the expression correlation information using element-by-element 
product of the two matrices. In this way, an integrated association matrix was 
compiled, where any association - positive or negative - that was in conflict with 
predicted target site information was removed. Distribution of filtered miRNA-
mRNA correlation coefficients was represented by a bimodal curve with two 
distinct peaks at the extreme end of correlation values lower than the peaks of 
the correlation coefficient distribution before filtering, indicating that most of 
miRNA-mRNA pairs showed no more correlation (Figure 12).  
Subsequently, the analysis focused on the identification of a potential network 
of miRNA-mRNA interactions. In order to address this issue, a biclustering 
approach on the integrated association matrix was adopted. Biclustering allows 
simultaneously clustering rows and columns of a matrix, grouping a subset of 
rows that exhibit similar behaviour across a subset of columns, or vice versa. In 
this case, biclustering was used to find a subset of mRNAs whit anti-correlation 
to miRNAs, outlining a group of genes that can potentially compete for binding 
to specific miRNAs. For this analysis was used the Plaid model biclustering 
which is more flexible and allows a gene to be in more than one cluster, or in 
none at all. The biclustering algorithm was iterated 100 times and extracted 
biclusters were evaluated in order to find the one with the maximum number of 
genes and miRNAs with an opposing correlation. Such analysis revealed a 
bicluster of 210 genes and 29 miRNAs with anti-correlation, indicating a 
potential miRNA-mRNA regulatory network during early human embryogenesis 
(Figure 13 and Figure 14). 
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Figure 13: Bubbleplot representing biclustering results 
Results 
 37 
 
Figure 14: Heatmap of the extracted bicluster 
 
The analysis of distribution of miRNA-mRNA correlation coefficients for such 
bicluster showed a strong anti-correlation, as indicated by the bimodal curve 
with a highest peak centred near -1 value (Figure 15). 
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Figure 15: Correlation distribution curve for the extracted bicluster 
 
Gene Ontology analysis of genes from this bicluster revealed that 49 out of 210 
are involved in embryonic development processes such as “regulation of 
embryonic development” (GO:0045995), “embryonic organ development” 
(GO:0048568), and “nervous system development” (GO:0007399). Moreover, 
hypergeometric test was performed to calculate statistical significance for over-
representation of embryo-related genes (corrected p-value <0.05). This analysis 
suggested that perturbations of the defined regulatory network of miRNAs and 
mRNAs could - in proof of principle - determine the alteration of normal 
embryonic development (Figure 16). 
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Figure 16: Biological processes over-representation of 210 genes of the selected bicluster 
 
6.3 Perturbation of miRNA-mRNA regulatory network during 
DS embryogenesis 
Starting from the hypothesis that during embryogenesis in DS embryos, HSA21 
genes may perturb the physiological miRNA-mRNA regulatory network, acting 
as sponges to sequester miRNAs, we found six HSA21 genes (ADAMTS5, 
AGPAT3, BACE2, ERG, HUNK, SLC5A3) in the selected miRNA-mRNA 
bicluster. However, as not all HSA21 genes are overexpressed in trisomic 
cells/tissue, we analyzed gene expression data in early DS embryo 
development. To this aim, RNA-Sequencing (RNA-Seq) datasets from 5 normal 
and 4 DS chorionic villi samples (Jin et al., 2013) were downloaded from GEO 
(accession number GSE42144) and analyzed, as described in the Methods 
Section. 
Raw reads in SRA format were first converted into FASTQ, and then it was 
evaluated the quality through FASTQC software. Per base and per sequence 
quality graphs showed a good quality of reads (Figure 17 and Figure 18). 
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Figure 17: Per base read quality 
 
 
Figure 18: Per sequence read quality 
Results 
 41 
 
Subsequently, RNA-Seq reads were mapped against the human reference 
genome hg19 using TopHat software. Quantification of gene expression levels 
by reads' counting and RPKM normalization were performed using RNASeqGUI 
package in R language (Russo and Angelini, 2014). RPKM counts distribution 
was analysed to assess samples variability (Figure 19). 
 
 
Figure 19: Box plot of RPKM counts distribution 
 
Similarities and differences among samples were highlighted performing a PCA 
(Principal Component Analysis). This analysis showed that euploid and DS 
samples were different enough to be considered two distinct groups, with the 
exception of sample EU2, which was discarded from further analyses (Figure 
20). 
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Figure 20: PCA plot of euploid and DS samples before (upper) and after (lower) removing EU2 
sample (red arrow). 
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Applying an arbitrary threshold of 1 RPKM, 14705 coding genes were detected 
as expressed in chorionic villi, 14044 of which were expressed in both 
conditions, 355 only in DS and 306 only in euploid samples. Differential 
expression analysis showed that 1221 genes were up-regulated in Down 
syndrome with 25 up-regulated HSA21 genes. Two out of six HSA21 genes - 
i.e. HUNK and BACE2 - are overexpressed in DS embryos and belong to the 
previously described bicluster of miRNA-mRNAs. Such network consists of 210 
potential ceRNAs and 29 miRNAs; however, not every mRNA is necessarily 
targeted by every miRNA. Indeed, ceRNA cross-regulation increases with the 
number of shared miRNAs and is weakened when a ceRNA pair is targeted by 
too many non-shared miRNAs. Thus, the number of MREs and the anti-
correlation values of HUNK and BACE2 genes with the miRNAs included in the 
selected bicluster were analysed. HUNK and BACE2 genes were both 
predicted to interact with 19 out of 29 miRNAs contained in this bicluster. 
However, HUNK gene showed more negative anti-correlation values, and 
therefore it was selected for further in vitro studies.  
6.4 The role of HUNK as a ceRNA 
HUNK (hormonally up-regulated Neu-associated kinase) gene spans 171318 
bp on the forward strand of human chromosome 21q22 and consists of 11 
exons. HUNK is a sucrose non-fermenting 1 (Snf-1)/AMPK family of 
serine/threonine protein kinases member, that was first identified in the murine 
mammary gland (Gardner et al., 2000). AMPK family regulates cellular 
metabolism, stress responses and several processes relevant to tumorigenesis, 
including proliferation, differentiation, survival, and migration (Yeh et al., 2011). 
Consistently, Hunk is overexpressed in several human cancers and is involved 
in the onset and the metastasis of specific human mammary tumors (Yeh et al., 
2013). In situ hybridization showed that Hunk expression is developmentally 
regulated and tissue-specific in fetal mice and restricted to subsets of cells in 
the adult mouse (Gardner et al., 2000). Despite these findings suggest a role for 
Hunk in murine development, Hunk deletion in mice did not alter viability, 
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fertility, longevity, revealing HUNK is dispensable for normal development 
(Wertheim et al., 2009). 
The ability of HUNK to act as ceRNA during human embryogenesis was 
investigated in the course of this project overexpressing HUNK 3’UTR in 
HEK293 cell model. HEK293 cells were used since these cells are very easy to 
grow in culture and transfect very readily. Moreover, gene expression data from 
RNA-Seq experiments performed in our laboratory and from The Human 
Protein Atlas database indicated that HEK293 share 80% genes with embryonic 
samples. 
The 3’UTR is transcribed, but it is not translated into protein; however it can 
exert a regulatory function on gene expression through miRNA binding. HUNK 
3’UTR (4880 bp) was amplified by RT-PCR, cloned into expression plasmid 
pcDNA3.1 V5/His TOPO, and used to transfect HEK293 cell line. Empty 
pcDNA3.1 V5/His TOPO vector was used as control. According to the results of 
our computational analysis of the regulatory network, and in line with the 
ceRNA mechanism, HUNK 3’UTR overexpression should perturb the 
distribution of miRNAs on their targets, acting as a decoy for specific miRNAs. 
Consequently, as miRNAs are able to repress specific mRNAs, altering the 
expression level of a single ceRNA may have significant effect on other 
ceRNAs with shared MREs. Thus, we evaluated the expression of genes 
belonging to the ceRNA network 24, 30 and 48 hours after HUNK 3’UTR 
transfection by quantitative Real-Time PCR. First, endogenous HUNK gene 
expression was evaluated with specific primer pairs in the coding exons 10 and 
11. Results showed that overexpression of HUNK 3’UTR de-repressed HUNK 
transcript itself, inducing an overexpression of its endogenous transcript. 
Particularly, HUNK expression increased with increasing time after transfection 
(Figure 21). 
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Figure 21: HUNK expression 24, 30, 48 hours after HUNK 3'UTR transfection 
 
Then, the potential role of HUNK gene overexpression in the perturbation of 
embryogenesis in DS was further investigated. First, genes included in the 
selected bicluster were analysed in order to identify candidate genes involved in 
human embryogenesis. As previously cited, 49 out of 210 genes of the selected 
bicluster resulted to play a role in human embryogenesis, according to gene 
ontology (GO:0048568, GO:0045995, GO:0007399). Then, a comparative 
analysis with the genes differentially expressed in DS embryos was performed 
to assess whether some of these 49 embryo-related genes were up-regulated 
during DS embryogenesis. Hence, 8 embryo-related genes (BCL2, CLIC5, 
EPHA5, ERBB4, HIPK2, MECP2, ONECUT2, and WNT5A), included in the 
bicluster - and up-regulated in DS embryos - were selected, and their 
expression was evaluated in HUNK 3’UTR transfected samples (Figure 22). 
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Figure 22: Gene expression after HUNK 3'UTR transfection 
 
Overexpression of HUNK 3’UTR determined an increase of BCL2, CLIC5, 
EPHA5, ERBB4, HIPK2, MECP2, ONECUT2, and WNT5A genes expression 
levels, confirming the computational analysis used to define the miRNA/mRNA 
network.  
Since HUNK 3’UTR may act as decoy for the miRNAs belonging to this ceRNA 
network, the expression of 6 selected miRNAs (miR-17, miR-20a, miR-20b, 
miR-128, miR-200c, and miR-205) was investigated. To this end, quantitative 
Real-Time PCR was performed in transfected cells 24 and 30 hours after 
transfection (Figure 23).  
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Figure 23: miRNA expression in HEK293 cells 24 and 30 hours after HUNK 3'UTR transfection 
 
Notably, in line with our hypothesis, all miRNAs but miR-205 showed a 
decrease of expression, suggesting they are sequestered by the 3’UTR of 
HUNK gene. 
Then, to test whether the ceRNA effect of HUNK gene was due to a specific 
region of its 3’UTR, and in turn to specific MREs, HUNK 3’UTR was divided into 
5 overlapping fragments. Each fragment was amplified, cloned into pcDNA3.1 
V5/HIS TOPO vector and used to transfect HEK293 cells. Expression levels of 
BCL2, CLIC5, HIPK2, MECP2, ONECUT2, and WNT5A genes was analysed by 
quantitative Real-Time PCR (Figure 24). 
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Figure 24: Expression analysis of selected genes 24h after transfection of partial HUNK 3'UTR 
fragments 
 
Moreover, the expression of the six selected miRNAs was analysed through 
quantitative Real-Time PCR in cells transfected with partial HUNK 3’UTR 
fragments (Figure 25). 
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Figure 25: Expression analysis of selected miRNAs 24h after transfection of partial HUNK 3'UTR 
fragments 
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7 Discussion 
Down syndrome (DS) is the most frequent human aneuploidy, caused by an 
extra copy of all or part of human chromosome 21 (HSA21). DS is a complex 
genetic condition characterized by over 80 clinically different phenotypes of 
variable penetrance and expressivity. Individuals with DS show alterations - 
both structural and functional - affecting distinct organs and systems, 
suggesting a crucial role of Trisomy 21 in determining alterations of 
developmental processes. Thus, overexpression of individual genes cannot be 
considered independently when one considers phenotype–genotype 
correlations. Indeed, global gene deregulation suggests a more complex 
mechanism of gene expression regulation, which involves direct and/or indirect 
interactions among HSA21 gene products and genes located on the other 
chromosomes.  
This PhD project investigated the potential role of HSA21 genes - that are 
overexpressed in DS embryos - as competing endogenous RNA (ceRNA) 
during embryogenesis in foetuses with trisomy 21. The hypothesis is that these 
genes may act as miRNA "sponges", perturbing the expression of non-HSA21 
mRNAs involved in the organogenesis. The supernumerary copies of HSA21 
mRNAs would - in principle - disrupt the physiological mRNAs/miRNAs balance 
in DS embryos, thus affecting the miRNA-mediated gene silencing network that 
physiologically occurs during embryonic development. 
Using bioinformatics approaches and in vitro experimental validation, a potential 
regulatory network between miRNA and mRNA has been defined during the 
early stages of human development. It has been demonstrated that some 
HSA21 genes can crosstalk with other mRNAs through a competition for 
common miRNAs. Particularly, the results demonstrate that the 3’UTR of HUNK 
gene acts as decoy for miR-17, miR-20a, miR-20b, miR-128, and miR-200c. 
This "sponge" effect determines an increase of BCL2, CLIC5, EPHA5, ERBB4, 
HIPK2, MECP2, ONECUT2, and WNT5A expression levels.  
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Interestingly, MECP2 is essential for embryonic development. Its 
overexpression in mouse embryos leads to motor coordination deficit, 
impairment in learning and memory, hypotonia, severe mental retardation, 
recurrent infections. MECP2 encodes for methyl-CpG-binding protein 2 
(MeCP2), which binds specifically to methylated DNA and is able to repress 
transcription from methylated gene promoters. WNT5A (Wingless-Type MMTV 
Integration Site Family, Member 5A) gene is implicated in several 
developmental processes, including regulation of cell fate and patterning during 
embryogenesis. Its overexpression leads to severe outgrowth defects, including 
gastrointestinal, limbs, facial structures defects, and mental impairment. 
MECP2 and WNT5A overexpression in foetuses with DS are in agreement with 
the potential defects occurring during embryogenesis in DS. The results 
described in this project show that the multisystem alterations of Down 
syndrome may be caused, at least partly, by a competition between HSA21 and 
non-HSA21 transcripts for the same miRNAs. Such event is likely to occur in 
early stages of the embryonic development. These findings shed new light on 
HSA21 genes. Indeed, if data will be supported by further experimental 
evidences (e.g. cellular models of differentiation or animal models), it will confer 
a previously unrecognised role - encrypted in the mRNA itself and not linked to 
the protein-coding potential - to HSA21 genes in Down syndrome. This project 
has highlighted for the first time the existence of a crosstalk among mRNAs 
during human embryogenesis, demonstrating that HSA21 genes - that are 
overexpressed in DS embryos - and some developmentally relevant mRNAs 
"talk to each other using microRNA response elements, as letters of a new 
language". Concernedly, beyond their functioning as cis regulatory elements, 
UTRs can act as trans modulator of gene expression through miRNA binding, 
allowing RNA to communicate each other through the letters of the “ceRNA 
language”.  
This new regulatory layer, based on mRNA-miRNA interaction network, 
provides new perspectives to the study of human embryogenesis regulation and 
to the deregulation of key mechanisms of pathogenesis. Furthermore, it might 
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account for a portion of missing genetic and epigenetic variability in the etiology 
of diseases, particularly of DS. Thus, a novel dimension in gene regulation, 
based on cellular mRNAs and miRNAs homeostasis, is proposed herein. The 
disruption of this balance - caused for instance by HSA21 gene triplication - 
would affect crosstalk among ceRNAs, promoting genetic syndromes (like DS) 
due to aneuploidy or other similar genetic conditions linked to large 
chromosomal rearrangements. 
However, it remains to be established whether other HSA21 genes besides 
HUNK may exert a similar role of ceRNA during embryogenesis. In addition, 
animal model studies of embryogenesis and DS will be needed to clarify the 
regulatory network of miRNA-mRNA interactions during human development 
and the effect of perturbations of such network on phenotype manifestations. 
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